Kling Biotherapeutics

Join us as we celebrate 🎉Bella Monica, Senior Research Associate at #KlingBio for our July #EmployeeSpotlight!   At Kling, we are proud supporters of highlighting our outstanding team in our monthly Employee Spotlight Series, which showcases each team members achievements, work accomplishments, successes and interests!   The team at Kling are dedicated to developing a robust pipeline of therapeutic antibodies targeting novel antigens discovered using our best-in-class primary B-cell screening platform technologies, Kling-Select and Kling-Evolve targeting illnesses which include #cancer and #infectiousdiseases.   #drugdiscovery #immunooncology #antibodytherapeutics #drugdevelopment

Looking to the future at what lies ahead in #cancerresearch, our CSO, Stefano Gullà spoke with Megan Thomas at Drug Discovery World (DDW) to discuss how Artificial Intelligence🖥will play an increasing role in both research and clinical development of next generation cancer treatments! Stefano commented 'With ongoing advances in technology, the landscape is poised for continued innovation and the development of transformative therapies that will improve patient outcomes and ultimately lead to better cancer prevention, diagnosis, and treatment strategies.' 📰 Find the Global Cancer Research Guide on page 40 in #DDW’s Summer issue 2024 here: https://bit.ly/3XGUYgl

Check out our CSO Stefano Gullà as he speaks with Stephen Adams of Optimum Strategic Communications in the latest #optimumtv 📺 episode!   Stefano provides insight into #Kling’s proprietary B cell immortalisation platform and its approach to leveraging disease fighting antibodies derived from 'elite responders.'   👀 Watch the full episode below 👇 and follow Kling on LinkedIn to learn more about how Kling’s best-in-class platform simultaneously screens for novel antigen targets and identifies fully human antibodies.   #drugdiscovery #immunooncology #antibodytherapeutics #drugdevelopment

We are thrilled to highlight one of our outstanding team members for our monthly #EmployeeSpotlight series. For June, we are shining a light on 🔦 Kelly Maijoor, Associate Scientist at #KlingBio! Using our groundbreaking, human B-cell immortalization and screening platform technology, we are dedicated to building a strong pipeline across #cancer and #infectiousdiseases to improve patient outcomes living with these illnesses. #drugdiscovery #immunooncology #antibodytherapeutics #drugdevelopment

We are excited to share our first #EmployeeSpotlight of the month – highlighting our amazing team members here at Kling Biotherapeutics as we continue to advance our best-in-class primary B-cell screening platform that efficiently identifies therapeutic targets and antibodies to help patients battling illnesses which include #cancer and #infectiousdiseases. We are proud to introduce 📢 Casper Marsman, B Cell Platform Lead at #KlingBio! #drugdiscovery #immunooncology #antibodytherapeutics #drugdevelopment

We are proud to contribute to the discovery and advancement of new treatments for liver cancer with our participation in the innovative work spearheaded by Professor Ruchi Bansal.

Join Kling Biotherapeutics this May for Melanoma and Skin Cancer Awareness Month in raising awareness of the dangers of unprotected UV exposure from the sun - one of the main causes of #skincancer and one of the most preventable cancers.   Skin cancer is the 17th most common cancer worldwide and the main types are squamous cell carcinoma, basal cell carcinoma, and #melanoma. Data from the World Health Organization’s International Agency for Research on Cancer suggests the global total number of new melanoma cases will reach 413,100 per year by 2030.   Using our best-in-class primary B-cell immortalisation and screening platform, we have identified a first-in-class CD9 targeting #antibody derived from a melanoma survivor which binds to a unique, previously undiscovered epitope of CD9, leading to the development of our lead clinical program #KBA1412. KBA1412 is progressing in a Phase 1 clinical trial for solid tumor indications, demonstrating a clean safety profile.   Learn more about Kling's approach to leveraging disease fighting #antibodies derived from elite responders using the link in the first comment below.   #knowyourskin #becauseicheckedmyskin #sharethefacts #MelanomaAwareness #immunooncology #antibodytherapeutics #drugdevelopment #drugdiscovery

Join our CEO, Michael Koslowski and CSO, Stefano Gullà at #BioEquityEurope2024, from 12 - 14 May in San Sebastian, Spain! 📧 Hear the latest developments on Kling Biotherapeutics’ approach to leveraging disease fighting antibodies derived from elite responders by scheduling a 1-1 meeting with the team using the link in the comments below. Alternatively reach out directly on LinkedIn for more information. #Kling's best-in-class primary B-cell screening platform efficiently identifies therapeutic targets and antibodies from B-cells of ‘exceptional responders’, which, having been developed in the human body, have shown to be safe and effective in helping these individuals successfully battle illnesses including #cancer and #infectiousdiseases. For more than 20 years, Bio€quity Europe has been where CEOs and investors gather to network, partner, and debate critical issues facing the biotech industry. #BioEquityEurope #BioEquity2024 #drugdiscovery #immunooncology #antibodytherapeutics 

Our CSO Stefano Gullà had a fantastic day at the 20th Annual Anglonordic Life Science Conference 2024 yesterday in London! Stefano presented on Kling Biotherapeutics' best-in-class primary B-cell immortalization and screening platform that efficiently identifies therapeutic targets and #antibodies.   The remainder of the day was full of insightful panel discussions and enjoyable #networking opportunities spent catching up with familiar faces and making new connections.   Learn more about #Kling's approach to leveraging disease fighting antibodies derived from elite responders using the link in the first comment below. #drugdiscovery #immunooncology #antibodytherapeutics #drugdevelopment

This Thursday, at the 20th Annual Anglonordic Life Science Conference, our Chief Scientific Officer Stefano Gullà will be presenting on Kling Biotherapeutics’ groundbreaking, human B-cell immortalization and screening platform technology!   Join Stefano at 10.30 BST on Thursday 18 April, where he will provide an update on #Kling's discovery of new therapeutic targets and antibodies by interrogating patient-derived B cells.   Get in touch with us to arrange a meeting at the conference or reach out on the partnering platform.   #drugdevelopment #drugdiscovery #immunooncology #antibodytherapeutics